Advanced Oncotherapy PLC Total Voting Rights (6231E)
June 30 2023 - 11:00AM
UK Regulatory
TIDMAVO
RNS Number : 6231E
Advanced Oncotherapy PLC
30 June 2023
30 June 2023
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Total Voting Rights
Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the
next-generation proton therapy system for cancer treatment,
announces that the Company's issued share capital as at the date of
this announcement comprises 542,573,869 ordinary shares of 25 pence
each, with one voting right per share ("Ordinary Shares"). The
Company does not hold any ordinary shares in treasury and therefore
the total number of Ordinary Shares with voting rights in the
Company is 542,573,869. This announcement is required to be made at
month end in accordance with the FCA's Disclosure Guidance and
Transparency Rules.
Rule 2.9 disclosure
In accordance with Rule 2.9 of the Takeover Code, AVO confirms
that, at the close of business on 29 June 2023 its issued share
capital consisted of 542,573,869 ordinary shares of 25 pence each.
The International Securities Identification Number for the
Company's ordinary shares is GB00BD6SX109.
Advanced Oncotherapy plc www.avoplc.com
Dr. Michael Sinclair, Executive Chairman Tel: +44 (0) 20 3617 8728
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad and
Joint Broker)
Nick Athanas / Piers Shimwell (Corporate Tel: +44 (0) 20 3328 5656
Finance)
Amrit Nahal / Matt Butlin (Sales
and Corporate Broking)
SI Capital Ltd (Joint Broker)
Nick Emerson Tel: +44 (0) 1483 413 500
Jon Levinson Tel: +44 (0) 20 3871 4066
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy, a UK headquartered company with offices in
London, Geneva, The Netherlands and in the USA, is a provider of
particle therapy with protons that harnesses the best in modern
technology. Advanced Oncotherapy's team "ADAM," based in Geneva,
focuses on the development of a proprietary proton accelerator
called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's
compact configuration delivers proton beams in a way that
facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with innovative
technology as well as expected lower treatment-related side
effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVREASKEDSPDEFA
(END) Dow Jones Newswires
June 30, 2023 12:00 ET (16:00 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2023 to Apr 2024